Intratect

Human Normal Immunoglobulin, the active ingredient in Intratect, is an Immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity by supplying pooled IgG antibodies to patients with primary or secondary immunodeficiency and to those with certain immune‑mediated disorders.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality and regulatory compliance across global markets.

Intratect is used in several immunodeficiency and immune‑mediated disease pathways. - Primary immunodeficiency diseases: restores antibody levels to reduce infection frequency. - Secondary immunodeficiency (e.g., chemotherapy, HIV): supplies needed IgG to support immune function. - Kawasaki disease: reduces inflammation and prevents coronary artery complications. - Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑immune activity. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability.

Intratect may be associated with a range of adverse reactions, varying from mild infusion‑related events to rare but serious complications.

Common Side Effects: - Headache: mild to moderate pain often occurring during or after infusion. - Fever and chills: transient rise in temperature and shaking sensations. - Fatigue: general tiredness that may last several hours. - Nausea or vomiting: gastrointestinal discomfort following administration. - Myalgia: muscle aches commonly reported during infusion. - Infusion‑related erythema: redness at the site or generalized flushing.

Serious or Rare Side Effects: - Aseptic meningitis: severe headache with neck stiffness requiring medical evaluation. - Thromboembolic events: blood clots such as deep‑vein thrombosis or stroke. - Acute renal failure: sudden loss of kidney function, especially with high‑dose regimens. - Hemolytic anemia: destruction of red blood cells leading to jaundice or fatigue. - Anaphylaxis: life‑threatening allergic reaction with airway compromise. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Intratect therapy, clinicians should consider several precautionary measures to minimize risks. - Assess renal function: evaluate baseline creatinine and adjust infusion rate if impaired. - Monitor for thrombotic risk: screen for history of clotting disorders or cardiovascular disease. - Screen for IgA deficiency: patients with anti‑IgA antibodies may develop severe reactions. - Use appropriate infusion rate: start slowly and increase gradually to reduce adverse events. - Avoid in patients with known severe hypersensitivity to immunoglobulin products. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Live vaccines: concurrent use may diminish vaccine efficacy and increase infection risk. - Additional immunoglobulin products: may cause immunoglobulin overload and renal stress. - High‑dose aspirin or NSAIDs: increase risk of renal impairment when combined with IVIG.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): IVIG may potentiate anticoagulant effect, requiring INR monitoring. - Diuretics: combined use can heighten risk of renal dysfunction. - ACE inhibitors: may augment blood pressure fluctuations during infusion. - Corticosteroids: may mask early signs of infection, necessitating careful observation.